851 results on '"Heckman, Caroline A."'
Search Results
2. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
3. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling
4. Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
5. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial
6. Robust scoring of selective drug responses for patient-tailored therapy selection
7. Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity
8. Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia
9. Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia
10. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
11. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
12. An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
13. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
14. Improving drug sensitivity predictions in precision medicine through active expert knowledge elicitation
15. Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia
16. Bipartite network models to design combination therapies in acute myeloid leukaemia
17. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
18. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
19. Immunogenomic Landscape of Hematological Malignancies
20. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window
21. Prognostic significance of esterase gene expression in multiple myeloma
22. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
23. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
24. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition
25. KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia
26. FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
27. Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
28. Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
29. Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
30. Combined gene essentiality scoring improves the prediction of cancer dependency maps
31. Venetoclax triggers sub-lethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
32. A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow
33. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML
34. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
35. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting
36. Robust scoring of selective drug responses for patient-tailored therapy selection
37. Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
38. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
39. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma
40. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
41. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer
42. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
43. Germline alterations in a consecutive series of acute myeloid leukemia
44. S175: SINGLE-CELL ANALYSIS REVEALS SOMATIC TP53 MUTATIONS EMERGE IN EARLY PROGENITOR CELLS BUT BECOME ENRICHED IN THE ERYTHROID LINEAGE IN ERCC6L2 DISEASE
45. P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
46. PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES
47. P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
48. Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
49. Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
50. Personalizing precision medicine : Patients with AML perceptions about treatment decisions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.